Cargando…

FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab

INTRODUCTION: Targeting costimulatory receptors of the tumor necrosis factor receptor (TNFR) superfamily with agonistic antibodies is a promising approach in cancer immuno therapy. It is known that their efficacy strongly depends on FcγR cross-linking. METHODS: In this study, we made use of a Jurkat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leitner, Judith, Egerer, Ricarda, Waidhofer-Söllner, Petra, Grabmeier-Pfistershammer, Katharina, Steinberger, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413977/ https://www.ncbi.nlm.nih.gov/pubmed/37575254 http://dx.doi.org/10.3389/fimmu.2023.1208631

Ejemplares similares

BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM
por: Battin, Claire, et al.
Publicado: (2022)

Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
por: Chin, S. Michael, et al.
Publicado: (2018)

T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells
por: Leitner, Judith, et al.
Publicado: (2010)

Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents
por: Battin, Claire, et al.
Publicado: (2023)

Immune correlates of Varlilumab treated cancer patients are consistent with CD27 costimulatory activity
por: Bullock, Timothy, et al.
Publicado: (2014)

Not All Immune Checkpoints Are Created Equal
por: De Sousa Linhares, Annika, et al.
Publicado: (2018)

TIM-3 Does Not Act as a Receptor for Galectin-9
por: Leitner, Judith, et al.
Publicado: (2013)

Production and N-glycan engineering of Varlilumab in Nicotiana benthamiana
por: Nguyen, Kim Dua, et al.
Publicado: (2023)

Saturated very long-chain fatty acids regulate macrophage plasticity and invasiveness
por: Zierfuss, Bettina, et al.
Publicado: (2022)

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells
por: Stecher, Carmen, et al.
Publicado: (2017)

Lack of Induction of RBD-Specific Neutralizing Antibodies despite Repeated Heterologous SARS-CoV-2 Vaccination Leading to Seroconversion and Establishment of T Cell-Specific Memory in a Patient in Remission of Multiple Myeloma
por: Kratzer, Bernhard, et al.
Publicado: (2022)

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma
por: Timmerman, John, et al.
Publicado: (2020)

Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity
por: Reitinger, Carmen, et al.
Publicado: (2022)

The effects of Cyclosporine A and azathioprine on human T cells activated by different costimulatory signals
por: Leitner, Judith, et al.
Publicado: (2011)

Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
por: Ramakrishna, Venky, et al.
Publicado: (2015)

Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)
por: Aschmoneit, Nadine, et al.
Publicado: (2022)

Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer
por: Hong, David S., et al.
Publicado: (2022)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Interrogating ligand-receptor interactions using highly sensitive cellular biosensors
por: Funk, Maximilian A., et al.
Publicado: (2023)

Low seroprotection rate for meningococcus serogroup C in the adult HIV-1-infected population in Austria
por: Grabmeier-Pfistershammer, Katharina, et al.
Publicado: (2019)

A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors
por: Cohen, Ezra E. W., et al.
Publicado: (2019)

The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent
por: He, Li-Zhen, et al.
Publicado: (2015)

Combined assessment of S‐ and N‐specific IL‐2 and IL‐13 secretion and CD69 neo‐expression for discrimination of post–infection and post‐vaccination cellular SARS‐CoV‐2‐specific immune response
por: Kratzer, Bernhard, et al.
Publicado: (2022)

Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions
por: Qureshi, O. S., et al.
Publicado: (2017)

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
por: Hamid, Omid, et al.
Publicado: (2022)

Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131)
por: Mimoto, F., et al.
Publicado: (2013)

Costimulatory pathways in transplantation
por: Pilat, Nina, et al.
Publicado: (2011)

Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors
por: Isoda, Yuya, et al.
Publicado: (2015)

Late versus non-late presentation of HIV/AIDS: an economic impact analysis
por: Grabmeier-Pfistershammer, K, et al.
Publicado: (2010)

The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
por: ROŽMAN, SAMO, et al.
Publicado: (2016)

Differential Use of Human Neutrophil Fcγ Receptors for Inducing Neutrophil Extracellular Trap Formation
por: Alemán, Omar Rafael, et al.
Publicado: (2016)

The Diverse Functions of the Ubiquitous Fcγ Receptors and Their Unique Constituent, FcRγ Subunit
por: Hamdan, Thamer A., et al.
Publicado: (2020)

RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial
por: Lim, Sean H., et al.
Publicado: (2018)

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
por: Sanborn, Rachel E, et al.
Publicado: (2022)

Synergistic effects of agonistic costimulatory antibodies adsorbed to amphiphilic poly(γ-glutamic acid) nanoparticles
por: Freiburghaus, Catja, et al.
Publicado: (2013)

Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody
por: Kasturirangan, Srinath, et al.
Publicado: (2017)

FcγRIIa and FcγRIIIa genes polymorphism in Egyptian children with primary immune thrombocytopenia
por: Zakaria, Marwa, et al.
Publicado: (2023)

Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2
por: Wines, Bruce D., et al.
Publicado: (2021)

Cobas Ampliprep/Cobas TaqMan HIV-1 v2.0 Assay: Consequences at the Cohort Level
por: Taylor, Ninon, et al.
Publicado: (2013)

Fcγ receptor targeting in RA
por: Takai, Toshiyuki, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_du8huih7lf477s15sj32g87r3q